Fragment 176-191 cut weight gain and fat mass in obese mice

Has HGH Fragment 176-191 been tested in humans?

No human clinical trial has tested HGH Fragment 176-191. Every published study of it is preclinical: rodent tissue, whole-animal models, and one experiment on isolated human fat tissue in a lab dish ^[1]⁠^[2]⁠^[3].

No published human pharmacokinetic data exist for the unmodified 176-191 peptide. No controlled trial has measured body composition change in people who inject it, and no trial has established an effective human dose.

The evidence grade is D, limited. The preclinical mechanism is coherent and replicated across four separate studies. The parent compound has no human trials, and its closest tested relative failed its primary human endpoint.

What is HGH Fragment 176-191?

HGH Fragment 176-191 is a synthetic 16-amino-acid peptide corresponding to the C-terminal tail of human growth hormone. The idea behind it dates to the early 1990s. Researchers wanted to know whether GH's fat-metabolizing activity and its growth-promoting, glucose-raising activity live in different parts of the molecule. If they do, the fat-metabolism domain could be isolated and the rest left behind.

That question was answered in rats. What did not follow is a clean transfer of the answer into human outcome data for the peptide being sold.

The naming is tangled. Some foundational papers use "177-191" numbering for the same fragment. Later work modified the sequence by adding a tyrosine for stability, producing AOD9604. Gray-market listings labeled "Frag 176-191" typically refer to the unmodified original sequence. These are related but not identical molecules, and the human trial history belongs almost entirely to the modified one.

How is Fragment 176-191 different from somatropin?

Somatropin is full-length recombinant human growth hormone, a 191-amino-acid molecule, while Fragment 176-191 is a 16-amino-acid piece of its tail. Somatropin binds the GH receptor directly, drives IGF-1 production, and has a decades-deep clinical trial record in diagnosed GH deficiency.

Fragment 176-191 is a different compound. It is the C-terminal fragment isolated because it appeared to carry the parent hormone's fat-metabolism activity without the growth-promoting, receptor-binding parts ^[1]. That fragment is the basis of AOD9604 and of the products marketed as fat-loss peptides.

Conflating the two is the single biggest source of confusion, and it runs in both directions. Forums import GH-replacement expectations onto a product never dosed in a human trial, while medical sites address only legitimate full-length GH replacement and never cover what is sold as a research peptide. Growth hormone's own trial record on body composition and strength covers what the full-length hormone does.

How does Fragment 176-191 work?

Fragment 176-191's proposed mechanism is independent of the GH receptor: it inhibits fat storage and, in some preparations, promotes fat breakdown without receptor binding ^[1]⁠^[3]⁠^[4].

In ob/ob mice, AOD9604 increased fat oxidation and lipolysis without binding the GH receptor, without inducing hyperglycemia, and without reducing insulin secretion ^[4]. Stripping out the receptor-mediated, IGF-1-driving effects of full hGH while keeping the fat-metabolism activity was the design goal.

The earliest work on the parent fragment (177-191) found it reproduced intact hGH's antilipogenic action in rat adipose tissue almost identically, inhibiting fat synthesis. That first study did not find a significant separate lipolytic effect ^[1].

Later work filled the gap. An oral analog increased lipolytic activity and decreased lipogenic activity in obese rodents, and the same pattern held when researchers tested it on isolated human adipose tissue outside a living body ^[3].

What did the Fragment 176-191 animal studies find?

Four studies, all in animals or in tissue outside the body, found consistent antilipogenic effects and, in later preparations, lipolytic effects ^[1]⁠^[2]⁠^[3]⁠^[4].

• 1993, rat tissue. Wu et al. synthesized the 177-191 fragment and tested it in rat adipose tissue. It inhibited lipogenesis with activity comparable to intact hGH and did not produce a significant lipolytic effect on its own in that model ^[1]. The first paper found fat-storage inhibition, not strong direct fat burning.
• 1994, obese mice. Natera et al. gave chronic doses to obese (ob/ob) mice and found reduced cumulative weight gain and adipose tissue mass over time, with significant inhibition of lipogenesis ^[2]. The fragment behaves as a distinct functional domain of GH rather than an inert leftover piece.
• 2000, obese rodents and human tissue. Heffernan et al. tested an oral analog (AOD-9401) in obese rodents and again found reduced weight gain, with increased lipolytic and decreased lipogenic activity. Isolated human adipose tissue exposed to the compound in the lab showed the same response ^[3].
• 2001, obese mice. Heffernan et al. used the further-modified AOD9604 in ob/ob mice and reported reduced weight gain, increased fat oxidation and lipolysis, no binding to the GH receptor, no induced hyperglycemia, and no reduction in insulin secretion ^[4].

The 2001 mouse result is the origin of the "no diabetogenic effect" claim. It was demonstrated in mice, for a modified analog, and not for the peptide most people inject.

Together the four papers support a coherent story: a GH-receptor-independent mechanism in the hormone's C-terminus can inhibit fat storage and, in some forms, promote fat breakdown, without the receptor-mediated effects on glucose and growth that full-length GH produces. That is a legitimate scientific finding. It does not reach "this works for fat loss in humans," because every dose-response relationship, safety signal, and efficacy outcome comes from rodents or a single dish of human tissue.

What happened when AOD9604 was tested in people?

AOD9604 failed. The modified, patented analog went through six randomized controlled trials totaling roughly 893 participants, and its pivotal 24-week Phase IIb efficacy trial did not reach statistical significance for weight loss. The obesity development program was terminated in 2007.

That failure is the single most informative data point in the molecule's history. It is the only large controlled human test of the fragment concept, it ran on a molecule engineered to be more stable and effective than the original, and it did not clear the bar. Most forum and vendor-adjacent write-ups leave it out.

The result also does not transfer cleanly in the other direction. A failed trial of a modified analog is not a measurement of the unmodified peptide, which remains untested. AOD-9604's pivotal obesity trial covers that program in detail.

Does injecting Fragment 176-191 near belly fat target belly fat?

No. Nothing in the mechanism studies describes a localized effect. The rat and mouse data measure whole-body adipose tissue mass and systemic lipogenesis and lipolysis markers ^[1]⁠^[2]⁠^[4]. The human tissue experiment exposed isolated fat cells directly to the compound in a lab dish, not through a nearby subcutaneous injection ^[3].

A peptide injected under the skin diffuses into surrounding tissue and then into systemic circulation, like any other subcutaneously delivered peptide. It does not create a local depot with elevated action on nearby fat cells beyond what a hormone does anywhere else it reaches.

Even taking the lipolytic mechanism at face value, "inject it near your stomach to target belly fat" is not a claim the pharmacology supports. It is forum folklore.

Does Fragment 176-191 build muscle or strength?

None of the studies cited below addresses muscle or strength for Fragment 176-191. The mechanism is lipolytic and antilipogenic, operating on fat tissue metabolism rather than skeletal muscle protein synthesis.

Claims about added lean mass, strength gains, or performance benefits from this fragment are unsupported rather than merely unproven, because none of the studies cited below examines them.

Where does the 250 to 500 mcg dose come from?

The 250 to 500 mcg range comes from forum consensus, not from a trial protocol. No published human dose-finding study exists for the unmodified peptide.

The animal data do contain real, narrow effect sizes. In obese mice, chronic fragment treatment produced measurable reductions in cumulative body weight gain and adipose tissue mass compared with untreated controls, alongside significant inhibition of lipogenesis ^[2]. That is a dose-response signal in a rodent obesity model, and it cannot supply a human dose, a human timeframe, or a human magnitude of fat loss. What peptide dosing research tests covers how often circulating protocols work this way.

What is unknown about Fragment 176-191?

Fragment 176-191's human dose, safety, stability, and long-term effects are all uncharacterized:

• Dose. No human dose-finding study exists.
• Safety. Human safety data are limited to user-reported injection-site irritation, flushing, headache, and occasional fatigue or water retention, none of which has been systematically tracked.
• Stability in solution. Whether a given vial still contains intact, active peptide at the time of injection has not been characterized for this compound the way it has for some others.
• Purity and sterility. Gray-market supply is unverified by definition. How to read a peptide COA covers what a vendor's own test document establishes.
• Long-term use. Chronic human use has not been studied, so its effects are unknown.

Anyone claiming confident fat-loss or body-composition outcomes for Fragment 176-191 is extrapolating past what the evidence supports, including the best human attempt at testing the mechanism.